A Phase 1/2 interventional study of IMM-1-104 Monotherapy (Treatment Group A) and IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) in Advanced Solid Tumor, Pancreatic Adenocarcinoma and Malignant Melanoma (Cutaneous), sponsored by Immuneering Corporation. Active, not recruiting at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Immuneering Corporation · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Melanoma, Cutaneous Malignant with a site in United States — 3 open to participants now, 5 under way, 1 of them phase 3. Melanoma, Cutaneous Malignant · United States.
Among the 10 studies in Melanoma, Cutaneous Malignant with a site in United States, this one is one of 2 that started in 2022, is one of 2 in phase 1/2, and was the 7th registered.
17 studies on the registry are indexed under Melanoma, Cutaneous Malignant; 5 are open to participants now.
Browse Melanoma, Cutaneous Malignant studies →3 of the 10 studies in Melanoma, Cutaneous Malignant with a site in United States are open now. Recruiting first, the newest first:
Immatics US, Inc. · Sites in United States, Canada, France and 3 more countries
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 1–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Melanoma, Cutaneous Malignant studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 1
First in 1999; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 209 is above the median of 33 across 11 interventional studies indexed under Melanoma, Cutaneous Malignant.
Median enrollment 156 across the 7 interventional studies, 1,368 across the 3 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 9 most frequent:
Immuneering Corporation is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Immuneering Corporation has 2 studies filed under Melanoma, Cutaneous Malignant — fewer than ten, so there is no comparison to draw.
1 of the studies in Melanoma, Cutaneous Malignant with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05585320Immuneering CorporationA Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Melanoma, Cutaneous Malignant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have or cytologically confirmed diagnosis as follows:
Participants must be treatment naive or received prior systemic standard-of-care treatment as follows:
Monotherapy Phase 2a:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IMM-1-104 monotherapy for first/second line pancreatic adenocarcinoma; first/second/third line melanoma; or second/third line non small cell lung cancer
Drug: IMM-1-104 Monotherapy (Treatment Group A)
IMM-1-104 in combination with modified gemcitabine and nab-paclitaxel (mGnP) for first line pancreatic adenocarcinoma
Drug: IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)
IMM-1-104 in combination with modified FOLFIRINOX (mFFX) for first line pancreatic adenocarcinoma
Drug: IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
IMM-1-104 in combination with dabrafenib for second/third line post-IO melanoma with BRAF mutation
Drug: IMM-1-104 + dabrafenib (Treatment Group D)
IMM-1-104 in combination with pembrolizumab for second/third line post-IO melanoma
Drug: IMM-1-104 + pembrolizumab (Treatment Group E)
Once-daily, oral IMM-1-104 dose administered in 28-day cycles until treatment discontinuation criteria are met
Also known as: IMM-1-104
Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of gemcitabine and nab-paclitaxel until treatment discontinuation criteria are met. Gemcitabine will be administered at a dose of 1000 mg/m\^2 nab-Paclitaxel will be administered at a dose of 125 mg/m\^2
Also known as: IMM-1-104 + mGnP
Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of modified FOLFIRNOX until treatment discontinuation criteria are met. FOLFIRINOX will be administered as follows: Folinic Acid will be administered at 400 mg/m\^2 Fluorouracil will be administered at 2400 mg/m\^2 Irinotecan will be administered at 150 mg/m\^2 Oxaliplatin will be administered at 85 mg/m\^2
Also known as: IMM-1-104 + mFFX
Drug page: Dabrafenib
Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with twice daily oral dose of dabrafenib until treatment discontinuation criteria are met. Dabrafenib will be administered at a dose of 150mg daily (75mg twice daily).
Also known as: IMM-1-104 + dabrafenib
Drug page: Pembrolizumab
Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of pembrolizumab in sequence or concurrently depending on the enrolled cohort (two sub cohorts) until treatment discontinuation criteria are met. Pembrolizumab will be administered at a dose of 400mg.
Also known as: IMM-1-104 + pembro
Phase 1: Adverse Events
Number of participants with adverse events
Time frame: From treatment initiation through 30 days following the last IMM-1-104 dose
Phase 1: Dose-Limiting Toxicities
Number of participants with dose-limiting toxicities
Time frame: The first 21 days of study treatment
Phase 1: Recommended Phase 2 Candidate Optimal Dose
Selection of candidate optimal dose to take forward into Ph2a
Time frame: Initiation of study treatment through 21 days (up to approximately 18 months)
Phase 2a: Overall Response Rate
The proportion of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR), based on RECIST 1.1 criteria
Time frame: After up to 48 weeks (12 cycles) of study treatment
Phase 1/2a: Maximum Observed Plasma Concentration of IMM-1-104
Cmax
Time frame: After 12 weeks (3 Cycles) of study treatment
Phase 1/2a: Time to Reach Maximum Plasma Concentration of IMM-1-104
Tmax
Time frame: After 12 weeks (3 Cycles) of study treatment
Phase 1/2a: Area Under Plasma Concentration (AUC) Time Curve of IMM-1-104
AUC0-t
Time frame: After 12 weeks (3 Cycles) of study treatment
Phase 2a: Disease Control Rate (DCR)
The proportion of participants who have a best overall response (BOR) of stable disease (SD) or better
Time frame: After 16 weeks (4 Cycles) of study treatment
Phase 2a: Progression Free Survival (PFS)
The time interval between study treatment start and disease progression or death due to any cause.
Time frame: Up to approximately 2 years
Phase 2a: Duration of Response (DOR)
The time interval between an assessment of partial response (PR) or better and disease progression or death due to any cause.
Time frame: Up to approximately 2 years.
Phase 2a: Landmark 3-Month Survival
The proportion of participants who are still alive after three months on study.
Time frame: After 3 months of study participation.
Phase 2a: Landmark 6-Month Survival
The proportion of participants who are still alive after six months on study.
Time frame: After 6 months of study participation.
Phase 2a: Overall Survival (OS)
The time interval between study treatment start and death due to any cause.
Time frame: Up to approximately 2 Years
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Jun 2027, 56 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2027 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dabrafenib · Pembrolizumab
Melanoma, Cutaneous Malignant →
Immuneering Corporation